PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32621549-3 2020 Previous studies reported the pharmacological benefits of ALA such as glycemic control, improved insulin sensitivity and alleviation of diabetic complications such as neuropathy and cardiovascular diseases. Thioctic Acid 58-61 insulin Homo sapiens 97-104 33199187-14 2021 In summary, ALA supplementation improves serum insulin and insulin resistance in a two-class and duration dependent non-linear analysis. Thioctic Acid 12-15 insulin Homo sapiens 47-54 33199187-14 2021 In summary, ALA supplementation improves serum insulin and insulin resistance in a two-class and duration dependent non-linear analysis. Thioctic Acid 12-15 insulin Homo sapiens 59-66 33199187-9 2021 The findings of the meta-analysis showed that ALA supplementation significantly reduced insulin (WMD: -0.64; CI: -1.287 to 0.004, P = .04), HOMA-IR (WMD: -0.48; 95% CI: -0.79 to -0.16; P = .002). Thioctic Acid 46-49 insulin Homo sapiens 88-95 33199187-11 2021 Moreover, the effect of ALA on insulin was duration-dependent (Pnon-linearity = 0.04). Thioctic Acid 24-27 insulin Homo sapiens 31-38 32418411-12 2020 Indeed, emerging data support inositol and alpha-lipoic acid as alternative compounds, alone or in combination with the aforementioned strategies, with favourable effects on ovulation, insulin resistance and inflammation. Thioctic Acid 43-60 insulin Homo sapiens 185-192 33376686-7 2020 Metformin plus TA therapy reduced fasting blood glucose, glycated hemoglobin, and IR and showed increment in the insulin sensitivity (P < 0.01) with insignificant effect on fasting insulin (P = 0.09) compared with metformin monotherapy. Thioctic Acid 15-17 insulin Homo sapiens 113-120 31304823-9 2019 All treatments demonstrated specific positive effects: MYO modulated more hormonal profiles and OGTT in polycystic ovary syndrome (PCOS) with no familial diabetes, ALA improved insulin response to OGTT and metabolic parameters in all patients with no effects on reproductive hormones, MYO + ALA improved hormonal and metabolic aspects and insulin response to OGTT in all patients. Thioctic Acid 164-167 insulin Homo sapiens 177-184 31317814-12 2020 In conclusion, the combination of ALA and MI showed to be useful as long-term therapy in PCOS women, providing a normalization of the menstrual cycle and an amelioration of insulin levels with a high tolerability. Thioctic Acid 34-37 insulin Homo sapiens 173-180 31790890-7 2020 RESULTS: Patients treated with ALA at T1 and T2 showed a significant reduction in serum glucose, insulin, homeostatic model assessment-insulin resistance, and serum uric acid (P = 0.013, P = 0.002, P = 0.002, P <0.001; respectively) and significantly higher values of base excess (P < 0.001), compared with the control group. Thioctic Acid 31-34 insulin Homo sapiens 97-104 31790890-7 2020 RESULTS: Patients treated with ALA at T1 and T2 showed a significant reduction in serum glucose, insulin, homeostatic model assessment-insulin resistance, and serum uric acid (P = 0.013, P = 0.002, P = 0.002, P <0.001; respectively) and significantly higher values of base excess (P < 0.001), compared with the control group. Thioctic Acid 31-34 insulin Homo sapiens 135-142 31304823-9 2019 All treatments demonstrated specific positive effects: MYO modulated more hormonal profiles and OGTT in polycystic ovary syndrome (PCOS) with no familial diabetes, ALA improved insulin response to OGTT and metabolic parameters in all patients with no effects on reproductive hormones, MYO + ALA improved hormonal and metabolic aspects and insulin response to OGTT in all patients. Thioctic Acid 164-167 insulin Homo sapiens 339-346 31453617-6 2019 Although no change (p < 0.05) in serum glucose was observed, alpha-lipoic acid-supplemented subjects demonstrated reduced fasting serum insulin (p = 0.04) and HOMA-IR (p = 0.07) compared with the placebo group. Thioctic Acid 64-81 insulin Homo sapiens 139-146 31453617-8 2019 Study results suggest that alpha-lipoic acid supplementation may be a useful strategy to improve insulin sensitivity in pre-diabetic subjects but is not effective in modulating serum lipids. Thioctic Acid 27-44 insulin Homo sapiens 97-104 31176103-0 2019 Alpha lipoic acid and metformin alleviates experimentally induced insulin resistance and cognitive deficit by modulation of TLR2 signalling. Thioctic Acid 0-17 insulin Homo sapiens 66-73 31343010-6 2019 alpha-LA supplementation resulted in a statistically significant elevation in the quantitative insulin sensitivity check index (QUICKI) (P = 0.033), serum levels of adiponectin (P = 0.008) and adiponectin-to-leptin ratio (P = 0.007) compared to the placebo. Thioctic Acid 0-8 insulin Homo sapiens 95-102 31343010-9 2019 According to the results, alpha-LA supplementation for 12 weeks improved insulin resistance, serum levels of insulin, adiponectin and leptin without changing anthropometric measures, serum liver enzymes, resistin and irisin. Thioctic Acid 26-34 insulin Homo sapiens 73-80 31343010-9 2019 According to the results, alpha-LA supplementation for 12 weeks improved insulin resistance, serum levels of insulin, adiponectin and leptin without changing anthropometric measures, serum liver enzymes, resistin and irisin. Thioctic Acid 26-34 insulin Homo sapiens 109-116 31176103-4 2019 METHODS: In this study, the effect of alpha-lipoic acid (ALA) has been examined in rodent model of zymosan induced insulin resistance and cognitive deficits, targeting at TLR-2 signalling. Thioctic Acid 38-55 insulin Homo sapiens 115-122 31176103-4 2019 METHODS: In this study, the effect of alpha-lipoic acid (ALA) has been examined in rodent model of zymosan induced insulin resistance and cognitive deficits, targeting at TLR-2 signalling. Thioctic Acid 57-60 insulin Homo sapiens 115-122 31176103-8 2019 RESULTS: Daily treatment with ALA for 28 days (50, 100, 200 mg/kg, ip) significantly improved insulin sensitivity and cognitive performance in mice by decreasing insulin resistance, corticosterone, IL-6 levels, acetylcholinesterase enzyme activity and oxidative stress in liver, cortex and hippocampus. Thioctic Acid 30-33 insulin Homo sapiens 94-101 31176103-8 2019 RESULTS: Daily treatment with ALA for 28 days (50, 100, 200 mg/kg, ip) significantly improved insulin sensitivity and cognitive performance in mice by decreasing insulin resistance, corticosterone, IL-6 levels, acetylcholinesterase enzyme activity and oxidative stress in liver, cortex and hippocampus. Thioctic Acid 30-33 insulin Homo sapiens 162-169 31176103-10 2019 Combination of ALA (100 mg/kg, ip) with metformin (100 mg/kg, ip) exhibited a potentiating effect in improving cognitive performance and insulin signalling. Thioctic Acid 15-18 insulin Homo sapiens 137-144 31176103-11 2019 CONCLUSION: The findings of the study supported the hypothesis that TLR-2 induced inflammation leads to insulin resistance and cognitive impairment and provides an evidence for the therapeutic effect of ALA in IR and ADRD patients. Thioctic Acid 203-206 insulin Homo sapiens 104-111 30627435-0 2018 Insulin autoimmune syndrome in an Argentine woman taking alpha-lipoic acid: A case report and review of the literature. Thioctic Acid 57-74 insulin Homo sapiens 0-7 30983607-2 2019 Metformin and alpha-lipoic acid, two types of insulin-sensitizing agents, have been demonstrated to reduce insulin levels and improve insulin sensitivity. Thioctic Acid 14-31 insulin Homo sapiens 46-53 30983607-2 2019 Metformin and alpha-lipoic acid, two types of insulin-sensitizing agents, have been demonstrated to reduce insulin levels and improve insulin sensitivity. Thioctic Acid 14-31 insulin Homo sapiens 107-114 30983607-2 2019 Metformin and alpha-lipoic acid, two types of insulin-sensitizing agents, have been demonstrated to reduce insulin levels and improve insulin sensitivity. Thioctic Acid 14-31 insulin Homo sapiens 107-114 29696608-8 2018 As far as the authors of the present study are concerned, this is the first study, which evaluated aging associated with p38 and p53 pathways, oxidative stress parameters, and the expression of insulin in beta cells of an aged rat and reaffirmed the fact that ALA has a significant antioxidant role in reducing the aging process. Thioctic Acid 260-263 insulin Homo sapiens 194-201 30311825-10 2018 Daily supplementation with an individualized ALA, carnosine, and thiamine supplement effectively reduced glucose concentration in type 2 diabetic patients, probably by increasing insulin production from the pancreas. Thioctic Acid 45-48 insulin Homo sapiens 179-186 27377964-0 2016 Alpha-lipoic acid attenuates endoplasmic reticulum stress-induced insulin resistance by improving mitochondrial function in HepG2 cells. Thioctic Acid 0-17 insulin Homo sapiens 66-73 30286558-11 2018 CONCLUSION: ALA may be an effective supplement to improve antioxidant defense and insulin resistance in critically ill patients. Thioctic Acid 12-15 insulin Homo sapiens 82-89 29090431-0 2018 Modulatory effects of alpha-lipoic acid (ALA) administration on insulin sensitivity in obese PCOS patients. Thioctic Acid 22-39 insulin Homo sapiens 64-71 29090431-0 2018 Modulatory effects of alpha-lipoic acid (ALA) administration on insulin sensitivity in obese PCOS patients. Thioctic Acid 41-44 insulin Homo sapiens 64-71 29090431-5 2018 RESULTS: ALA administration significantly decreased insulin, glucose, BMI and HOMA index. Thioctic Acid 9-12 insulin Homo sapiens 52-59 28434274-0 2017 Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action. Thioctic Acid 26-43 insulin Homo sapiens 132-139 25905290-18 2000 Non-botanical nutraceutical agents with promise for improving insulin sensitivity and glycemic control include alpha-lipoic acid, chromium picolinate, magnesium, and resveratrol. Thioctic Acid 111-128 insulin Homo sapiens 62-69 30286558-3 2018 The aim of this study was to determine whether intervention with alpha-lipoic acid (ALA) influences the oxidative stress, insulin resistance, and clinical outcomes in critically ill patients. Thioctic Acid 65-82 insulin Homo sapiens 122-129 30286558-3 2018 The aim of this study was to determine whether intervention with alpha-lipoic acid (ALA) influences the oxidative stress, insulin resistance, and clinical outcomes in critically ill patients. Thioctic Acid 84-87 insulin Homo sapiens 122-129 28976801-0 2018 Alpha-Lipoic Acid Shows Promise to Improve Migraine in Patients with Insulin Resistance: A 6-Month Exploratory Study. Thioctic Acid 0-17 insulin Homo sapiens 69-76 28976801-1 2018 Alpha-lipoic acid (ALA) is known to lower insulin resistance (IR), which is common among migraineurs. Thioctic Acid 0-17 insulin Homo sapiens 42-49 28976801-1 2018 Alpha-lipoic acid (ALA) is known to lower insulin resistance (IR), which is common among migraineurs. Thioctic Acid 19-22 insulin Homo sapiens 42-49 27377964-1 2016 Alpha-lipoic acid (ALA) has been reported to have beneficial effects for improving insulin sensitivity. Thioctic Acid 0-17 insulin Homo sapiens 83-90 27377964-1 2016 Alpha-lipoic acid (ALA) has been reported to have beneficial effects for improving insulin sensitivity. Thioctic Acid 19-22 insulin Homo sapiens 83-90 27377964-4 2016 In this study, we investigated the effect of ALA on the modulation of insulin resistance in ER-stressed HepG2 cells, and we explored the potential mechanism of this effect. Thioctic Acid 45-48 insulin Homo sapiens 70-77 27377964-8 2016 Pretreatment of the ER stress cell model with ALA for 24h improved insulin sensitivity, restored the expression levels of mitochondrial oxidative phosphorylation (OXPHOS) complexes and increased intracellular ATP production. Thioctic Acid 46-49 insulin Homo sapiens 67-74 27377964-10 2016 Importantly, ALA treatment could decrease oligomycin-induced mitochondrial dysfunction and then improved insulin resistance. Thioctic Acid 13-16 insulin Homo sapiens 105-112 27377964-11 2016 Taken together, our data suggest that ALA prevents ER stress-induced insulin resistance by enhancing mitochondrial function. Thioctic Acid 38-41 insulin Homo sapiens 69-76 26769360-0 2016 Lipoic acid improves neuronal insulin signalling and rescues cognitive function regulating VGlut1 expression in high-fat-fed rats: Implications for Alzheimer"s disease. Thioctic Acid 0-11 insulin Homo sapiens 30-37 26721419-9 2016 Insulin was able to partially reverse the inhibitory action of alpha-LA on chemerin secretion. Thioctic Acid 63-71 insulin Homo sapiens 0-7 26651260-4 2016 RESULTS: Improvement and prevention of progression of NIS-LL (DeltaNIS-LL>=2 points) with ALA vs. placebo after 4 years was predicted by higher age, lower BMI, male sex, normal blood pressure, history of cardiovascular disease (CVD), insulin treatment, longer duration of diabetes and neuropathy, and higher neuropathy stage. Thioctic Acid 93-96 insulin Homo sapiens 237-244 24111525-0 2014 Insulin autoimmune syndrome (Hirata Disease) in European Caucasians taking alpha-lipoic acid. Thioctic Acid 75-92 insulin Homo sapiens 0-7 26491824-10 2015 Of these, we found to be interesting the association with monacolin K, a natural statin that reduces cholesterol levels starting point of the synthesis of steroids, including androgens, and lipoic acid, known for its anti-inflammatory, antioxidant and insulin-sensitizing activity. Thioctic Acid 190-201 insulin Homo sapiens 252-259 26171398-6 2015 We speculate that alpha-lipoic acid might have an antioxidant effect in pediatric diabetes patients by reducing insulin. Thioctic Acid 18-35 insulin Homo sapiens 112-119 25033564-3 2014 It was established that single administration of emoxipine, reamberin, mexidol and alpha-lipoic acid in optimal doses, corresponding to the therapeutic range in humans, increased the sensitivity of animals to insulin according to the criterion of insulin coma development. Thioctic Acid 83-100 insulin Homo sapiens 209-216 25033564-5 2014 Standardization of obtained data by average difference from the control and further correlation analysis demonstrated that the extent of antidepressant action of emoxipine, reamberin, mexidol and alpha-lipoic acid considerably depends on their insulin potentiating activity (r = 0.762, p = 0.004). Thioctic Acid 196-213 insulin Homo sapiens 244-251 23313466-0 2013 Reply to manuscript IJC-D-12-04197 entitled "Does alpha-lipoic acid treatment play a role on oxidative stress and insulin resistance in overweight/obese patients?" Thioctic Acid 50-67 insulin Homo sapiens 114-121 23200266-0 2013 Does alpha-lipoic acid treatment play a role on oxidative stress and insulin resistance in overweight/obese patients? Thioctic Acid 5-22 insulin Homo sapiens 69-76 24051942-0 2013 [Evaluation of a new association between insulin-sensitizers and alpha-lipoic acid in obese women affected by PCOS]. Thioctic Acid 65-82 insulin Homo sapiens 41-48 23981814-11 2013 CONCLUSIONS: Inositol combined with alpha lipoic acid can be used as a dietary supplement in insulin-resistant patients in order to increase their insulin sensitiveness. Thioctic Acid 36-53 insulin Homo sapiens 93-100 24002405-10 2013 Supplementation with omega-3 fatty acids, alpha-lipoic acid and N-acetylcysteine is considered to have an anti-inflammatory and antioxidant effect and to improve dyslipidemia and insulin sensitivity in PCOS women. Thioctic Acid 42-59 insulin Homo sapiens 179-186 23875003-0 2013 Age-dependent modulation of synaptic plasticity and insulin mimetic effect of lipoic acid on a mouse model of Alzheimer"s disease. Thioctic Acid 78-89 insulin Homo sapiens 52-59 23875003-4 2013 3xTg-AD mice fed 0.23% w/v lipoic acid in drinking water for 4 weeks showed an insulin mimetic effect that consisted of increased brain glucose uptake, activation of the insulin receptor substrate and of the PI3K/Akt signaling pathway. Thioctic Acid 27-38 insulin Homo sapiens 79-86 23875003-6 2013 Lipoic acid was more effective in stimulating an insulin-like effect and reversing the impaired synaptic plasticity in the old mice, wherein the impairment of insulin signaling and synaptic plasticity was more pronounced than those in young mice. Thioctic Acid 0-11 insulin Homo sapiens 49-56 22402059-2 2013 The aim of this study was to investigate the effect of treatment with the antioxidant alpha-lipoic acid (ALA) with or without vitamin E supplementation, on markers of insulin resistance and systemic inflammation and plasma nonesterified fatty acid (NEFA) concentrations in individuals with the metabolic syndrome. Thioctic Acid 86-103 insulin Homo sapiens 167-174 24116330-3 2013 AIM: This study was intended to assess the effects of antioxidants; alpha lipoic acid (ALA), omega 3 fatty acid and vitamin E on parameters of insulin sensitivity (blood glucose and HbA1c) in patients of type 2 diabetes mellitus with documented insulin resistance. Thioctic Acid 68-85 insulin Homo sapiens 143-150 24116330-3 2013 AIM: This study was intended to assess the effects of antioxidants; alpha lipoic acid (ALA), omega 3 fatty acid and vitamin E on parameters of insulin sensitivity (blood glucose and HbA1c) in patients of type 2 diabetes mellitus with documented insulin resistance. Thioctic Acid 87-90 insulin Homo sapiens 143-150 24116330-15 2013 CONCLUSION: ALA, Omega 3 fatty acid and vitamin E can be used as add on therapy in patients with type 2 diabetes mellitus to improve insulin sensitivity and lipid metabolism. Thioctic Acid 12-15 insulin Homo sapiens 133-140 22528396-0 2012 alpha-Lipoic acid protects 3T3-L1 adipocytes from NYGGF4 (PID1) overexpression-induced insulin resistance through increasing phosphorylation of IRS-1 and Akt. Thioctic Acid 0-17 insulin Homo sapiens 87-94 23285432-1 2012 OBJECTIVES: This study intended to assess the effects of the antioxidants; Alpha Lipoic Acid (ALA), omega 3 fatty acids and vitamin E on the parameters of insulin sensitivity, oxidative stress, lipid metabolism and glycaemic control in patients of type 2 diabetes mellitus. Thioctic Acid 75-92 insulin Homo sapiens 155-162 23285432-1 2012 OBJECTIVES: This study intended to assess the effects of the antioxidants; Alpha Lipoic Acid (ALA), omega 3 fatty acids and vitamin E on the parameters of insulin sensitivity, oxidative stress, lipid metabolism and glycaemic control in patients of type 2 diabetes mellitus. Thioctic Acid 94-97 insulin Homo sapiens 155-162 23285432-10 2012 CONCLUSION: ALA, omega 3 fatty acids and vitamin E showed the improvement in insulin sensitivity. Thioctic Acid 12-15 insulin Homo sapiens 77-84 21163347-5 2011 The beneficial interactions between the antioxidant alpha-lipoic acid and the advanced glycation end-product inhibitor pyridoxamine that ameliorate oxidant stress-associated defects in whole-body and skeletal-muscle insulin action in the obese Zucker rat, a model of prediabetes, are also addressed. Thioctic Acid 52-69 insulin Homo sapiens 216-223 21240346-2 2011 It was found that the preparations producing prooxidant effect in vitro (alpha-lipoic acid and reamberin) are characterized by pronounced insulin-potentiating activity, but only slightly increase (alpha-lipoic acid) or even decrease (reamberin) tolerance to glucose load. Thioctic Acid 73-90 insulin Homo sapiens 138-145 21593803-12 2011 The results indicate that short-term treatment with ALA can improve insulin sensitivity and plasma lipid profile possibly through amelioration of oxidative stress and chronic inflammatory reaction in obese patients with IGT. Thioctic Acid 52-55 insulin Homo sapiens 68-75 21593803-3 2011 alpha-Lipoic acid (ALA) is a potent antioxidant with insulin sensitizing activity. Thioctic Acid 0-17 insulin Homo sapiens 53-60 21593803-3 2011 alpha-Lipoic acid (ALA) is a potent antioxidant with insulin sensitizing activity. Thioctic Acid 19-22 insulin Homo sapiens 53-60 21593803-8 2011 After treatment of ALA in obese-IGT patients, insulin sensitivity was improved, insulin sensitivity index (ISI) impressively enhanced by 41%. Thioctic Acid 19-22 insulin Homo sapiens 46-53 21593803-8 2011 After treatment of ALA in obese-IGT patients, insulin sensitivity was improved, insulin sensitivity index (ISI) impressively enhanced by 41%. Thioctic Acid 19-22 insulin Homo sapiens 80-87 21371770-2 2011 This study evaluated the effects of supplementation with lipoic acid (LA) and alpha-tocopherol on the lipid profile and insulin sensitivity of DM2 patients. Thioctic Acid 57-68 insulin Homo sapiens 120-127 19601918-7 2009 A potent anti-oxidant and free radical scavenger, ALA also targets cellular signal transduction pathways which increases glucose uptake and utilization, thus providing specific targeted therapy in the treatment of insulin resistance and diabetic neuropathy. Thioctic Acid 50-53 insulin Homo sapiens 214-221 18674421-9 2008 These signalling cascades are believed to be responsible for the insulin resistance and reduced insulin secretion, therefore the use of innocuous antioxidant substances such as vitamin C, E and the a-lipoic acid, is seen as a possible step for type 2 diabetic complications management. Thioctic Acid 200-211 insulin Homo sapiens 65-72 18972440-5 2008 ALA increased AMPK phosphorylation in the liver and in cultured liver cells, and dominant-negative AMPK partially prevented ALA-induced suppression of insulin-stimulated SREBP-1c expression. Thioctic Acid 124-127 insulin Homo sapiens 151-158 18972440-7 2008 CONCLUSION: These results show that ALA prevents fatty liver disease through multiple mechanisms, and suggest that ALA can be used to prevent the development and progression of nonalcoholic fatty liver disease in patients with insulin resistance. Thioctic Acid 115-118 insulin Homo sapiens 227-234 18571145-9 2008 A number of experimental as well as clinical studies point to the usefulness of ALA as a therapeutic agent for such diverse conditions as diabetes, atherosclerosis, insulin resistance, neuropathy, neurodegenerative diseases and ischemia-reperfusion injury. Thioctic Acid 80-83 insulin Homo sapiens 165-172 17329919-0 2007 Insulin Autoimmune Syndrome possibly caused by alpha lipoic acid. Thioctic Acid 53-64 insulin Homo sapiens 0-7 17302524-1 2007 In animal experiments, the potent antioxidant and free radical scavenger alpha-lipoic acid has been shown to cause weight loss, ameliorate insulin resistance and atherogenic dyslipidemia, as well as to lower blood pressure, all of these being components of the metabolic syndrome. Thioctic Acid 73-90 insulin Homo sapiens 139-146 16337874-6 2006 Recent investigations have demonstrated that the combination of exercise training and antioxidant treatment using ALA in an animal model of obesity-associated insulin resistance provides a unique interactive effect resulting in a greater improvement in insulin action on skeletal muscle glucose transport than either intervention individually. Thioctic Acid 114-117 insulin Homo sapiens 253-260 17178700-0 2006 Improvement of insulin sensitivity in patients with type 2 diabetes mellitus after oral administration of alpha-lipoic acid. Thioctic Acid 106-123 insulin Homo sapiens 15-22 17178700-2 2006 Alpha-lipoic acid has been shown to improve insulin action after parenteral administration. Thioctic Acid 0-17 insulin Homo sapiens 44-51 17178700-3 2006 OBJECTIVE: the aim of the study was to assess the effect of oral administration of alpha-lipoic acid on insulin sensitivity in patients with type 2 diabetes. Thioctic Acid 83-100 insulin Homo sapiens 104-111 17178700-8 2006 CONCLUSION: short-term oral alpha-lipoic acid treatment increases peripheral insulin sensitivity in patients with type 2 diabetes mellitus. Thioctic Acid 28-45 insulin Homo sapiens 77-84 16505238-6 2006 Antioxidants, including N-acetylcysteine, lipoic acid, or quercetin, only minimally induced the insulin promoter. Thioctic Acid 42-53 insulin Homo sapiens 96-103 16337874-0 2006 Exercise training and the antioxidant alpha-lipoic acid in the treatment of insulin resistance and type 2 diabetes. Thioctic Acid 38-55 insulin Homo sapiens 76-83 16337874-4 2006 Numerous studies have demonstrated that treatment of insulin-resistant animals and type 2 diabetic humans with antioxidants, including alpha-lipoic acid (ALA), is associated with improvements in skeletal muscle glucose transport activity and whole-body glucose tolerance. Thioctic Acid 135-152 insulin Homo sapiens 53-60 16337874-4 2006 Numerous studies have demonstrated that treatment of insulin-resistant animals and type 2 diabetic humans with antioxidants, including alpha-lipoic acid (ALA), is associated with improvements in skeletal muscle glucose transport activity and whole-body glucose tolerance. Thioctic Acid 154-157 insulin Homo sapiens 53-60 16337874-6 2006 Recent investigations have demonstrated that the combination of exercise training and antioxidant treatment using ALA in an animal model of obesity-associated insulin resistance provides a unique interactive effect resulting in a greater improvement in insulin action on skeletal muscle glucose transport than either intervention individually. Thioctic Acid 114-117 insulin Homo sapiens 159-166 16309849-4 2006 Indeed, bimoclomol--a heat shock protein co-inducer being developed for treatment of diabetic neuropathy--and lipoic acid--suspected to be a heat shock protein inducer--have each demonstrated favorable effects on the insulin sensitivity of obese rodents, and parenteral lipoic acid is reported to improve the insulin sensitivity of type 2 diabetics. Thioctic Acid 110-121 insulin Homo sapiens 217-224 16309849-4 2006 Indeed, bimoclomol--a heat shock protein co-inducer being developed for treatment of diabetic neuropathy--and lipoic acid--suspected to be a heat shock protein inducer--have each demonstrated favorable effects on the insulin sensitivity of obese rodents, and parenteral lipoic acid is reported to improve the insulin sensitivity of type 2 diabetics. Thioctic Acid 110-121 insulin Homo sapiens 309-316 16309849-4 2006 Indeed, bimoclomol--a heat shock protein co-inducer being developed for treatment of diabetic neuropathy--and lipoic acid--suspected to be a heat shock protein inducer--have each demonstrated favorable effects on the insulin sensitivity of obese rodents, and parenteral lipoic acid is reported to improve the insulin sensitivity of type 2 diabetics. Thioctic Acid 270-281 insulin Homo sapiens 217-224 16472075-0 2006 Synthesis, characterization and biological activity of chemically modified insulin derivative with alpha lipoic acid. Thioctic Acid 99-116 insulin Homo sapiens 75-82 16472075-1 2006 A novel chemically-modified insulin, epsilon-N(B29)-lipoyl insulin, was selectively prepared by the covalent linkage of alpha-lipoic acid (LA) to the epsilon-amino group of Lys(B29) of insulin without any protecting agent and analyzed by PAGE, HPLC, MALDI-TOF-MS. Monolipoyl- insulin maintained the glucose-lowering effect as well as native insulin and showed a longer duration of action than native insulin and an inhibitory effect towards trypsin degradation. Thioctic Acid 120-137 insulin Homo sapiens 28-35 16472075-1 2006 A novel chemically-modified insulin, epsilon-N(B29)-lipoyl insulin, was selectively prepared by the covalent linkage of alpha-lipoic acid (LA) to the epsilon-amino group of Lys(B29) of insulin without any protecting agent and analyzed by PAGE, HPLC, MALDI-TOF-MS. Monolipoyl- insulin maintained the glucose-lowering effect as well as native insulin and showed a longer duration of action than native insulin and an inhibitory effect towards trypsin degradation. Thioctic Acid 120-137 insulin Homo sapiens 59-66 16472075-1 2006 A novel chemically-modified insulin, epsilon-N(B29)-lipoyl insulin, was selectively prepared by the covalent linkage of alpha-lipoic acid (LA) to the epsilon-amino group of Lys(B29) of insulin without any protecting agent and analyzed by PAGE, HPLC, MALDI-TOF-MS. Monolipoyl- insulin maintained the glucose-lowering effect as well as native insulin and showed a longer duration of action than native insulin and an inhibitory effect towards trypsin degradation. Thioctic Acid 120-137 insulin Homo sapiens 59-66 16472075-1 2006 A novel chemically-modified insulin, epsilon-N(B29)-lipoyl insulin, was selectively prepared by the covalent linkage of alpha-lipoic acid (LA) to the epsilon-amino group of Lys(B29) of insulin without any protecting agent and analyzed by PAGE, HPLC, MALDI-TOF-MS. Monolipoyl- insulin maintained the glucose-lowering effect as well as native insulin and showed a longer duration of action than native insulin and an inhibitory effect towards trypsin degradation. Thioctic Acid 120-137 insulin Homo sapiens 59-66 16472075-1 2006 A novel chemically-modified insulin, epsilon-N(B29)-lipoyl insulin, was selectively prepared by the covalent linkage of alpha-lipoic acid (LA) to the epsilon-amino group of Lys(B29) of insulin without any protecting agent and analyzed by PAGE, HPLC, MALDI-TOF-MS. Monolipoyl- insulin maintained the glucose-lowering effect as well as native insulin and showed a longer duration of action than native insulin and an inhibitory effect towards trypsin degradation. Thioctic Acid 120-137 insulin Homo sapiens 59-66 16472075-1 2006 A novel chemically-modified insulin, epsilon-N(B29)-lipoyl insulin, was selectively prepared by the covalent linkage of alpha-lipoic acid (LA) to the epsilon-amino group of Lys(B29) of insulin without any protecting agent and analyzed by PAGE, HPLC, MALDI-TOF-MS. Monolipoyl- insulin maintained the glucose-lowering effect as well as native insulin and showed a longer duration of action than native insulin and an inhibitory effect towards trypsin degradation. Thioctic Acid 120-137 insulin Homo sapiens 59-66 16356119-7 2005 As can be expected, administration of antioxidants such as lipoic acid in oxidized cells, in animal models of diabetes, and in type 2 diabetes shows improved insulin sensitivity. Thioctic Acid 59-70 insulin Homo sapiens 158-165 16337874-7 2006 Moreover, this interactive effect of exercise training and ALA is due in part to improvements in IRS-1-dependent insulin signaling. Thioctic Acid 59-62 insulin Homo sapiens 113-120 14674712-4 2003 In an insulin resistant animal model of hypertension, spontaneously hypertensive rats (SHRs), dietary supplementation with lipoic acid lowers tissue aldehydes and plasma insulin levels and normalizes blood pressure. Thioctic Acid 123-134 insulin Homo sapiens 6-13 16335793-6 2005 Treatment with lipoic acid, an endogenous sulfur-containing fatty acid, normalizes insulin resistance and lowers tissue aldehyde conjugates, cytosolic [Ca2+]i, and blood pressure in spontaneously hypertensive rats (SHR). Thioctic Acid 15-26 insulin Homo sapiens 83-90 15998258-0 2005 Utilization of the insulin-signaling network in the metabolic actions of alpha-lipoic acid-reduction or oxidation? Thioctic Acid 73-90 insulin Homo sapiens 19-26 15998258-3 2005 It is suggested that alpha-lipoic acid through its prooxidant properties acutely stimulates the insulin-signaling cascade, thereby increasing glucose uptake in muscle and fat cells. Thioctic Acid 21-38 insulin Homo sapiens 96-103 15998258-4 2005 On the other hand, alpha-lipoic acid appears to protect the insulin-signaling cascade from oxidative stress-induced insulin resistance through its reducing capacities. Thioctic Acid 19-36 insulin Homo sapiens 60-67 15998258-4 2005 On the other hand, alpha-lipoic acid appears to protect the insulin-signaling cascade from oxidative stress-induced insulin resistance through its reducing capacities. Thioctic Acid 19-36 insulin Homo sapiens 116-123 15998258-6 2005 These different properties render alpha-lipoic acid a potentially attractive therapeutic agent for the treatment of insulin resistance. Thioctic Acid 34-51 insulin Homo sapiens 116-123 15998259-8 2005 Consistent with this idea, studies with antioxidants such as vitamin E, alpha-lipoic acid, and N-acetylcysteine indicate a beneficial impact on insulin sensitivity, and offer the possibility for new treatment approaches for insulin resistance. Thioctic Acid 72-89 insulin Homo sapiens 144-151 15998259-8 2005 Consistent with this idea, studies with antioxidants such as vitamin E, alpha-lipoic acid, and N-acetylcysteine indicate a beneficial impact on insulin sensitivity, and offer the possibility for new treatment approaches for insulin resistance. Thioctic Acid 72-89 insulin Homo sapiens 224-231 14674712-4 2003 In an insulin resistant animal model of hypertension, spontaneously hypertensive rats (SHRs), dietary supplementation with lipoic acid lowers tissue aldehydes and plasma insulin levels and normalizes blood pressure. Thioctic Acid 123-134 insulin Homo sapiens 170-177 11090300-6 2000 The antioxidant alpha lipoic acid has been shown to increase insulin sensitivity and is used to treat people with diabetes. Thioctic Acid 16-33 insulin Homo sapiens 61-68 12837769-2 2003 alpha-Lipoic acid (LA) has been demonstrated to activate the insulin signaling pathway and to exert insulin-like actions in adipose and muscle cells. Thioctic Acid 0-17 insulin Homo sapiens 61-68 12837769-2 2003 alpha-Lipoic acid (LA) has been demonstrated to activate the insulin signaling pathway and to exert insulin-like actions in adipose and muscle cells. Thioctic Acid 0-17 insulin Homo sapiens 100-107 11555840-0 2001 alpha-Lipoic acid prevents the development of glucose-induced insulin resistance in 3T3-L1 adipocytes and accelerates the decline in immunoreactive insulin during cell incubation. Thioctic Acid 0-17 insulin Homo sapiens 62-69 11555840-0 2001 alpha-Lipoic acid prevents the development of glucose-induced insulin resistance in 3T3-L1 adipocytes and accelerates the decline in immunoreactive insulin during cell incubation. Thioctic Acid 0-17 insulin Homo sapiens 148-155 11555840-3 2001 The antioxidant alpha-lipoic acid has been proposed as an insulin sensitizer. Thioctic Acid 16-33 insulin Homo sapiens 58-65 12715971-2 2003 This review will address the hypothesis that exercise training and the antioxidant R-(+)-lipoic acid interact at the level of insulin signaling to enhance glucose transport in insulin-resistant skeletal muscle. Thioctic Acid 83-100 insulin Homo sapiens 126-133 12715971-2 2003 This review will address the hypothesis that exercise training and the antioxidant R-(+)-lipoic acid interact at the level of insulin signaling to enhance glucose transport in insulin-resistant skeletal muscle. Thioctic Acid 83-100 insulin Homo sapiens 176-183 12682423-5 2003 Limited knowledge showing benefits of preconditioning with anti- oxidants (vitamin C, E, a-lipoic acid, N-acetylcysteine) in order to protect insulin action under oxidative stress prompted the author to discuss the theoretical background to this approach. Thioctic Acid 91-102 insulin Homo sapiens 142-149 11375349-2 2001 alpha-Lipoic acid enhances glucose uptake and GLUT1 and GLUT4 translocation in 3T3-L1 adipocytes and L6 myotubes, mimicking insulin action. Thioctic Acid 0-17 insulin Homo sapiens 124-131 11375349-9 2001 Like insulin, alpha-lipoic acid increased the kinase activity of the alpha (2.8-fold) and beta (2.1-fold) isoforms of p38 MAPK, measured by an in vitro kinase assay. Thioctic Acid 14-31 insulin Homo sapiens 5-12 10491755-2 1999 This study explores the potential of the antioxidant lipoic acid to protect the cells against the induction of insulin resistance when given before exposure to oxidative stress. Thioctic Acid 53-64 insulin Homo sapiens 111-118 11467343-0 2000 Alpha-lipoic acid: a multifunctional antioxidant that improves insulin sensitivity in patients with type 2 diabetes. Thioctic Acid 0-17 insulin Homo sapiens 63-70 10768090-0 2000 Engagement of the insulin-sensitive pathway in the stimulation of glucose transport by alpha-lipoic acid in 3T3-L1 adipocytes. Thioctic Acid 87-104 insulin Homo sapiens 18-25 10668913-1 1999 Thioctic acid (alpha-lipoic acid) has been shown to improve insulin-regulated glucose disposal in animal models of insulin resistance and type 2 diabetic patients. Thioctic Acid 0-13 insulin Homo sapiens 60-67 10668913-1 1999 Thioctic acid (alpha-lipoic acid) has been shown to improve insulin-regulated glucose disposal in animal models of insulin resistance and type 2 diabetic patients. Thioctic Acid 0-13 insulin Homo sapiens 115-122 10668913-1 1999 Thioctic acid (alpha-lipoic acid) has been shown to improve insulin-regulated glucose disposal in animal models of insulin resistance and type 2 diabetic patients. Thioctic Acid 15-32 insulin Homo sapiens 60-67 10668913-1 1999 Thioctic acid (alpha-lipoic acid) has been shown to improve insulin-regulated glucose disposal in animal models of insulin resistance and type 2 diabetic patients. Thioctic Acid 15-32 insulin Homo sapiens 115-122 10668913-6 1999 These data show that thioctic acid mimics insulin action by activating the signalling cascade at or before the level of phosphatidylinositol 3-kinase. Thioctic Acid 21-34 insulin Homo sapiens 42-49 10491755-5 1999 Lipoic acid pretreatment increased insulin-stimulated glucose transport following oxidative stress, reaching 84.8 +/- 4.4% of the control, associated with an increase in reduced glutathione content. Thioctic Acid 0-11 insulin Homo sapiens 35-42 10491755-7 1999 Lipoic acid pretreatment was, however, associated with preserved insulin-induced glucose transporter 4 translocation in cells exposed to oxidation, yielding 80% of its content in controls. Thioctic Acid 0-11 insulin Homo sapiens 65-72 10491755-8 1999 Although tyrosine phosphorylation patterns were not affected by lipoic acid pretreatment, insulin-stimulated protein kinase B/Akt serine 473 phosphorylation and activity were considerably impaired by oxidation but protected by lipoic acid pretreatment. Thioctic Acid 227-238 insulin Homo sapiens 90-97 10491755-10 1999 CONCLUSION/INTERPRETATION: This study shows the ability of lipoic acid to provide partial protection against the impaired insulin-stimulated glucose transporter 4 translocation and protein kinase B/Akt activation induced by oxidative stress, potentially by its capacity to maintain intracellular redox state. Thioctic Acid 59-70 insulin Homo sapiens 122-129 10468203-2 1999 Clinical studies described an increase of insulin sensitivity after acute and short-term (10 d) parenteral administration of ALA. Thioctic Acid 125-128 insulin Homo sapiens 42-49 10468203-9 1999 When compared to placebo, significantly more subjects had an increase in insulin-stimulated glucose disposal (MCR) after ALA treatment in each group. Thioctic Acid 121-124 insulin Homo sapiens 73-80 10468203-12 1999 This placebo-controlled explorative study confirms previous observations of an increase of insulin sensitivity in type-2 diabetes after acute and chronic intravenous administration of ALA. Thioctic Acid 184-187 insulin Homo sapiens 91-98 8817248-0 1996 Improvement of insulin-stimulated glucose-disposal in type 2 diabetes after repeated parenteral administration of thioctic acid. Thioctic Acid 114-127 insulin Homo sapiens 15-22 10468203-13 1999 The results suggest that oral administration of alpha-lipoic acid can improve insulin sensitivity in patients with type-2 diabetes. Thioctic Acid 48-65 insulin Homo sapiens 78-85 10609878-0 1999 Thioctic acid--effects on insulin sensitivity and glucose-metabolism. Thioctic Acid 0-13 insulin Homo sapiens 26-33 9252495-0 1997 Differential effects of lipoic acid stereoisomers on glucose metabolism in insulin-resistant skeletal muscle. Thioctic Acid 24-35 insulin Homo sapiens 75-82 9252495-1 1997 The racemic mixture of the antioxidant alpha-lipoic acid (ALA) enhances insulin-stimulated glucose metabolism in insulin-resistant humans and animals. Thioctic Acid 39-56 insulin Homo sapiens 72-79 9252495-1 1997 The racemic mixture of the antioxidant alpha-lipoic acid (ALA) enhances insulin-stimulated glucose metabolism in insulin-resistant humans and animals. Thioctic Acid 39-56 insulin Homo sapiens 113-120 9252495-1 1997 The racemic mixture of the antioxidant alpha-lipoic acid (ALA) enhances insulin-stimulated glucose metabolism in insulin-resistant humans and animals. Thioctic Acid 58-61 insulin Homo sapiens 72-79 9252495-1 1997 The racemic mixture of the antioxidant alpha-lipoic acid (ALA) enhances insulin-stimulated glucose metabolism in insulin-resistant humans and animals. Thioctic Acid 58-61 insulin Homo sapiens 113-120 9252495-5 1997 Acutely, R-(+)-ALA increased insulin-mediated 2-DG-uptake by 64% (P < 0.05), whereas S-(-)-ALA had no significant effect. Thioctic Acid 9-18 insulin Homo sapiens 29-36 9252495-6 1997 Although chronic R-(+)-ALA treatment significantly reduced plasma insulin (17%) and free fatty acids (FFA; 35%) relative to vehicle-treated obese animals, S-(-)-ALA treatment further increased insulin (15%) and had no effect on FFA. Thioctic Acid 17-26 insulin Homo sapiens 66-73 9252495-6 1997 Although chronic R-(+)-ALA treatment significantly reduced plasma insulin (17%) and free fatty acids (FFA; 35%) relative to vehicle-treated obese animals, S-(-)-ALA treatment further increased insulin (15%) and had no effect on FFA. Thioctic Acid 21-26 insulin Homo sapiens 66-73 9252495-7 1997 Insulin-stimulated 2-DG uptake was increased by 65% by chronic R-(+)-ALA treatment, whereas S-(-)-ALA administration resulted in only a 29% improvement. Thioctic Acid 63-72 insulin Homo sapiens 0-7 9252495-8 1997 Chronic R-(+)-ALA treatment elicited a 26% increase in insulin-stimulated glycogen synthesis and a 33% enhancement of insulin-stimulated glucose oxidation. Thioctic Acid 8-17 insulin Homo sapiens 55-62 9252495-8 1997 Chronic R-(+)-ALA treatment elicited a 26% increase in insulin-stimulated glycogen synthesis and a 33% enhancement of insulin-stimulated glucose oxidation. Thioctic Acid 8-17 insulin Homo sapiens 118-125 9252495-11 1997 Therefore, chronic parenteral treatment with the antioxidant ALA enhances insulin-stimulated glucose transport and non-oxidative and oxidative glucose metabolism in insulin-resistant rat skeletal muscle, with the R-(+) enantiomer being much more effective than the S-(-) enantiomer. Thioctic Acid 61-64 insulin Homo sapiens 74-81 9252495-11 1997 Therefore, chronic parenteral treatment with the antioxidant ALA enhances insulin-stimulated glucose transport and non-oxidative and oxidative glucose metabolism in insulin-resistant rat skeletal muscle, with the R-(+) enantiomer being much more effective than the S-(-) enantiomer. Thioctic Acid 61-64 insulin Homo sapiens 165-172 9275010-1 1997 Alpha-lipoic acid (ALA), a potent biological antioxidant, improves insulin action of skeletal muscle glucose transport and metabolism in both human and animal models of insulin resistance. Thioctic Acid 0-17 insulin Homo sapiens 67-74 9275010-1 1997 Alpha-lipoic acid (ALA), a potent biological antioxidant, improves insulin action of skeletal muscle glucose transport and metabolism in both human and animal models of insulin resistance. Thioctic Acid 0-17 insulin Homo sapiens 169-176 9275010-1 1997 Alpha-lipoic acid (ALA), a potent biological antioxidant, improves insulin action of skeletal muscle glucose transport and metabolism in both human and animal models of insulin resistance. Thioctic Acid 19-22 insulin Homo sapiens 67-74 9275010-1 1997 Alpha-lipoic acid (ALA), a potent biological antioxidant, improves insulin action of skeletal muscle glucose transport and metabolism in both human and animal models of insulin resistance. Thioctic Acid 19-22 insulin Homo sapiens 169-176 9275010-2 1997 In order to obtain further insight into the potential intracellular mechanisms for the action of ALA on insulin-stimulated glucose transport in skeletal muscle, we investigated the effects of direct incubation with ALA (2 mM) on 2-deoxyglucose (2-DG) uptake by epitrochlearis muscle from either insulin-sensitive lean (Fa/-) or insulin-resistant obese (fa/fa) Zucker rats. Thioctic Acid 97-100 insulin Homo sapiens 104-111 9275010-4 1997 The stimulation of 2-DG uptake due to ALA was enhanced 30-55% in the presence of insulin. Thioctic Acid 38-41 insulin Homo sapiens 81-88 8817248-7 1996 Parenteral administration of TA resulted in a significant increase of insulin-stimulated glucose-disposal by about 30% (metabolic clearance rate for glucose, 2.5 +/- 0.3 vs. 3.2 +/- 0.4 ml/kg/min and insulin-sensitivity-index: 3.5 +/- 0.5 vs. 4.7 +/- 0.4 mg/kg/microU/ml; p < 0.05, Wilcoxon-Rank-Sum-Test). Thioctic Acid 29-31 insulin Homo sapiens 70-77 8817248-7 1996 Parenteral administration of TA resulted in a significant increase of insulin-stimulated glucose-disposal by about 30% (metabolic clearance rate for glucose, 2.5 +/- 0.3 vs. 3.2 +/- 0.4 ml/kg/min and insulin-sensitivity-index: 3.5 +/- 0.5 vs. 4.7 +/- 0.4 mg/kg/microU/ml; p < 0.05, Wilcoxon-Rank-Sum-Test). Thioctic Acid 29-31 insulin Homo sapiens 200-207 34879186-10 2021 In subjects with T2D and definite stage of SAN, treatment with ALA resulted in a significant decrease of glucose, immunoreactive insulin concentration, and Homeostasis Model Assessment (HOMA)-IR (HOMA-IR) parameters; pulse wave velocity (PWV), aorta augmentation index (AIxao) during the active period of the day and decrease of PWV, AIxao, and brachial augmentation index during the passive period of the day compared with the results, obtained in the control group. Thioctic Acid 63-66 insulin Homo sapiens 129-136 34573969-3 2021 Therefore, we investigated the metabolic pathways in PBGD-silenced hepatocytes and assessed the efficacy of an insulin mimic, alpha-lipoic acid (alpha-LA), as a potential therapeutic strategy. Thioctic Acid 126-143 insulin Homo sapiens 111-118 34573969-3 2021 Therefore, we investigated the metabolic pathways in PBGD-silenced hepatocytes and assessed the efficacy of an insulin mimic, alpha-lipoic acid (alpha-LA), as a potential therapeutic strategy. Thioctic Acid 145-153 insulin Homo sapiens 111-118 35501295-7 2022 Also, fasting blood sugar (FBS), insulin, luteinizing hormone (LH), and LH/follicle stimulating hormone (FSH) levels were significantly lower in the MET+ALA group. Thioctic Acid 153-156 insulin Homo sapiens 33-40 35253180-1 2022 Alpha-lipoic acid (ALA) plays a key role in many physiological processes, exerting anti-inflammatory, immunomodulatory, antioxidant, detoxifying, and insulin sensitizing activities. Thioctic Acid 0-17 insulin Homo sapiens 150-157 35253180-1 2022 Alpha-lipoic acid (ALA) plays a key role in many physiological processes, exerting anti-inflammatory, immunomodulatory, antioxidant, detoxifying, and insulin sensitizing activities. Thioctic Acid 19-22 insulin Homo sapiens 150-157 35253180-2 2022 Since ALA improves insulin resistance (IR), it has been suggested that ALA could be beneficial it in the treatment of PCOS. Thioctic Acid 6-9 insulin Homo sapiens 19-26 35253180-2 2022 Since ALA improves insulin resistance (IR), it has been suggested that ALA could be beneficial it in the treatment of PCOS. Thioctic Acid 71-74 insulin Homo sapiens 19-26 7575750-6 1995 This is the first clinical study to show that alpha-lipoic acid increases insulin stimulated glucose disposal in NIDDM. Thioctic Acid 46-63 insulin Homo sapiens 74-81 33235302-2 2020 The antioxidant alpha-lipoic acid (ALA) has been shown to attenuate metabolic stress and improve insulin sensitivity in part through activation of the heat shock response (HSR). Thioctic Acid 16-33 insulin Homo sapiens 97-104 33235302-2 2020 The antioxidant alpha-lipoic acid (ALA) has been shown to attenuate metabolic stress and improve insulin sensitivity in part through activation of the heat shock response (HSR). Thioctic Acid 35-38 insulin Homo sapiens 97-104 33235302-4 2020 In the current investigation, we assessed whether ALA has an effect on modulating the expression of DNAJB3/HSP40 cochaperone; a potential therapeutic target with a novel role in mitigating metabolic stress and promoting insulin signaling. Thioctic Acid 50-53 insulin Homo sapiens 220-227 33235302-9 2020 In functional assays, ALA treatment abrogated significantly the tunicamycin-mediated transcriptional activation of ATF6 while it enhanced the insulin-stimulated glucose uptake and Glut4 translocation. Thioctic Acid 22-25 insulin Homo sapiens 142-149 33235302-11 2020 Furthermore, the effect of ALA on insulin-stimulated glucose uptake is significantly reduced in C2C12 and HepG2 cells transfected with DNAJB3 siRNA. Thioctic Acid 27-30 insulin Homo sapiens 34-41 34662650-1 2021 Lipoic acid (alpha lipoic acid, thioctic acid) is a popular over-the-counter antioxidant and insulin-mimetic supplement under investigation in a variety of conditions including multiple sclerosis, diabetes, and schizophrenia. Thioctic Acid 0-11 insulin Homo sapiens 93-100 34662650-1 2021 Lipoic acid (alpha lipoic acid, thioctic acid) is a popular over-the-counter antioxidant and insulin-mimetic supplement under investigation in a variety of conditions including multiple sclerosis, diabetes, and schizophrenia. Thioctic Acid 13-30 insulin Homo sapiens 93-100 34662650-1 2021 Lipoic acid (alpha lipoic acid, thioctic acid) is a popular over-the-counter antioxidant and insulin-mimetic supplement under investigation in a variety of conditions including multiple sclerosis, diabetes, and schizophrenia. Thioctic Acid 32-45 insulin Homo sapiens 93-100 35422650-0 2022 alpha-Lipoic Acid Reduces Ceramide Synthesis and Neuroinflammation in the Hypothalamus of Insulin-Resistant Rats, While in the Cerebral Cortex Diminishes the beta-Amyloid Accumulation. Thioctic Acid 0-17 insulin Homo sapiens 90-97 35422650-6 2022 Results: ALA normalizes body weight, food intake, glycemia, insulinemia, and systemic insulin sensitivity in HFD-fed rats. Thioctic Acid 9-12 insulin Homo sapiens 86-93 35422650-7 2022 ALA treatment reduces nicotinamide adenine dinucleotide phosphate (NADPH) and xanthine oxidase activity, increases ferric-reducing antioxidant power (FRAP) and thiol levels in the hypothalamus of insulin-resistant rats. Thioctic Acid 0-3 insulin Homo sapiens 196-203 35422650-10 2022 ALA improves systemic oxidative status and reduces insulin-resistant rats" serum cytokines, chemokines, and growth factors. Thioctic Acid 0-3 insulin Homo sapiens 51-58 35422650-11 2022 Conclusion: ALA normalizes lipid and carbohydrate metabolism in insulin-resistant rats. Thioctic Acid 12-15 insulin Homo sapiens 64-71 35422650-16 2022 Although further study is needed, ALA may be a potential treatment for patients with cerebral complications of insulin resistance. Thioctic Acid 34-37 insulin Homo sapiens 111-118 35327450-8 2022 Therefore, the use of liver-targeted insulin and insulin-mimetics such as alpha-lipoic acid may be useful for overcoming metabolic dysfunction in these subjects. Thioctic Acid 74-91 insulin Homo sapiens 49-56 35234312-7 2022 Moreover, alpha-LA increases insulin secretion, glucose transport, and insulin sensitivity. Thioctic Acid 10-18 insulin Homo sapiens 29-36 35234312-7 2022 Moreover, alpha-LA increases insulin secretion, glucose transport, and insulin sensitivity. Thioctic Acid 10-18 insulin Homo sapiens 71-78